Mirna Therapeutics has named Sinil Kim as its chief medical officer.
In this role, Kim will be responsible for the clinical development of Mirna’s phase I cancer drug MRX34, as well as other compounds in the firm’s pipeline, Mirna said.
Kim was most recently a senior director at Pfizer, serving as global clinical lead for two renal cancer drug programs. Before that, he was director of clinical oncology at Bristol-Myers Squibb.